Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Grasso

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Immune Based Therapies and Vaccines|December 24, 2010
Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin BBrian Drozdowski, Yuhong Zhou, Brad Kline, et al.
Oncotarget|September 2, 2015
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculatureKatherine Rybinski, Hongxia Z Imtiyaz, Barrie Mittica, et al.
Oncotarget|October 6, 2017
Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signaturesNiklas K Finnberg, Prashanth Gokare, Avital Lev, et al.
Cancer Immunity|March 10, 2007
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alphaWolfgang Ebel, Eric L Routhier, Brian Foley, et al.
Molecular Cancer Therapeutics|September 29, 2018
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor ActivityXin Cheng, Jing Li, Keigo Tanaka, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Cancer Biology & Therapy|September 13, 2013
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicityJianMin Lin, Jared L Spidel, Christopher J Maddage, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technologyJian Li, Tao Sai, Marc Berger, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Immune Based Therapies and Vaccines|December 24, 2010
Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin BBrian Drozdowski, Yuhong Zhou, Brad Kline, et al.
Oncotarget|September 2, 2015
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculatureKatherine Rybinski, Hongxia Z Imtiyaz, Barrie Mittica, et al.
Oncotarget|October 6, 2017
Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signaturesNiklas K Finnberg, Prashanth Gokare, Avital Lev, et al.
Cancer Immunity|March 10, 2007
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alphaWolfgang Ebel, Eric L Routhier, Brian Foley, et al.
Molecular Cancer Therapeutics|September 29, 2018
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor ActivityXin Cheng, Jing Li, Keigo Tanaka, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Cancer Biology & Therapy|September 13, 2013
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicityJianMin Lin, Jared L Spidel, Christopher J Maddage, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technologyJian Li, Tao Sai, Marc Berger, et al.
Pageof 4